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The glucagon receptor antagonist BI-32169, recently isolated from Streptomyces sp., was described
as a bicyclic peptide, although its primary structure comprises conserved elements of class I and
class II lasso peptides. Tandem mass spectrometric and nuclear magnetic resonance spectroscopic
studies revealed that BI-32169 is a lasso-structured peptide constituting the new class III of lasso
peptides. The determined lasso fold opens new avenues to improve the promising biological activity
of BI-32169.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Lasso peptides are ribosomally assembled, bioactive natural prod-
ucts of bacterial origin composed of 16–21 amino acids [1–6]. They
share an N-terminal 8/9-residue macrolactam ring, generated upon
a condensation reaction between the a-NH2 group of Gly1/Cys1
and the carboxyl side chain of Asp/Glu at position 8 or 9, through
which the linear, exocyclic C-terminal part is threaded (Fig. 1). Steri-
cally demanding side chains (e.g. Tyr or Arg) trap this threaded tail
within the macrocyclic ring and therefore stabilize the entropically
disfavored lasso fold. Lasso peptides are classiﬁed depending on
the presence (class I) or absence (class II) of four conserved Cys res-
idues, which are involved in the formation of two disulﬁde bonds,
resulting in a further rigidiﬁcation of the peptide [7]. Their biological
activities range from inhibition of HIV replication (RP 71955) [8] or of
myosin light chain kinase (MS-271) [9] to antibacterial activity (cap-
istruin) [1] and bacterial RNA polymerase inhibition (MccJ25)
[10,11]. In addition mutational analysis of the precursor proteins of
MccJ25 [12] and capistruin [13] revealed a low speciﬁcity of the
enzymatic machinery, which converts the ribosomal precursor into
the mature lasso peptide, and therefore these peptides are believed
to be interesting candidates for protein engineering efforts.
In a search for novel glucagon receptor antagonists, which are
promising candidates for a new antidiabetic therapy [14], the bicyclicchemical Societies. Published by E
91 (M.A. Marahiel).
,marahiel@staff.uni-marburg.19-residue peptide BI-32169 produced by Streptomyces sp. (DSM
14996) was discovered [15]. BI-32169 showed potent inhibitory
activity against the human glucagon receptor (IC50 440 nM) in a func-
tional cell-based assay. It is composed of an N-terminal 9-residue
macrolactam ring, which is formed by an isopeptide bond between
the a-NH2 group of the N-terminal Gly1 and the side chain carboxyl
group of Asp9. Additionally, the C-terminal cysteine (Cys19) of the
remaining 10-residue tail forms a disulﬁde bond with Cys6, which
is locatedwithin themacrolactam ring, resulting in a bicyclic primary
structure (Fig. 1A). In comparison to the primary structure of class I
and class II lasso peptides, BI-32169 seems to resemble a mixed type
of both classes, containing a Gly at position one and two cysteines
forming one disulﬁde bond. Due to the high similarity of the primary
structure, and as Streptomyces strains are known to produce both
class I and class II lasso peptides, we proposed, that BI-32169 has a
lasso structure. In this studywe performed tandemmass spectromet-
ric analysis of native and reduced BI-32169, and NMR spectroscopic
studies to determine the three-dimensional structure of the bicyclic
peptide. Our results clearly prove the lasso structure of BI-32169,
which constitutes the new class III of lasso peptides.2. Materials and methods
2.1. Fermentation and isolation of BI-32169
The BI-32169 producing strain Streptomyces sp. (DSM 14996)
was purchased from the German Collection of Microorganismslsevier B.V. All rights reserved.
Fig. 1. Lasso peptides. (A) Primary structures of currently known lasso peptides. (B) NMR structure of RP 71955 (PDB 1RPB). (C) NMR structure of capistruin (BMRB 20014).
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scale in 2 l bafﬂed ﬂasks containing 15–20 glass beads for myce-
lium disruption and 500 ml medium comprising glucose (2%),
caseinpeptone (0.4%), yeast extract (0.05%), meat extract (0.4%),
NaCl (0.5%) and CaCO3 (0.3%). The pH was adjusted to 7.2. Twenty
millilitres of a 48 h old preculture, which were grown in a medium
consisting of soybean meal (1.5%), glucose (1.5%), NaCl (0.5%),
CaCO3 (0.1%), KH2PO4 (0.03%), pH 7.2, were used to inoculate each
ﬂask [15]. Cells were grown for ﬁve days at 28 C and 160 rpm and
harvested by centrifugation. The mycelium was extracted twice
with 750 ml methanol to which 3.5 ml DMSO were added. The ex-
tract was evaporated to dryness and redissolved in 20 ml methanol
and 4 ml DMSO and ﬁnally applied onto a RP-HPLC preparative
Nucleodur C18ec column (250 mm  21 mm). Elution was per-
formed by applying the following gradient of water/0.1% TFA (sol-
vent A) and methanol/0.1% TFA (solvent B) at a ﬂow rate of
16 ml min1: linear increase from 10% B to 95% B within 36 min
followed by holding 95% B for additional 5 min. The retention time
of BI-32169 was 33.5 min.
2.2. Mass spectrometric analyses of BI-32169
The mass spectrometric characterization of native and reduced
BI-32169 was performed with an LTQ-FT instrument (Thermo Fish-
er Scientiﬁc, Bremen, Germany) connected to a microbore 1100
HPLC system (Agilent, Waldbronn, Germany). To analyze the re-
duced state, 1 mg BI-32169 was dissolved in 1 ml 50 mM Na2HPO4,
6 M GdmCl, pH 8.0 and reduced in a 100 ll reaction in the presence
of 20 mMDTT for 30 min at 25 C. Reoxidation of reduced BI-32169
was performed by exposure to air for 72 h at 25 C. Subsequently
20 ll were analyzed by HPLC–MS. Separation of BI-32169 from
contaminants was achieved using a 125/2 Nucleodur C18ec col-
umn (Macherey-Nagel, Dueren, Germany). Following gradient of
water/0.05% formic acid (solvent A) and acetonitrile/0.045% formic
acid (solvent B) was applied at a column temperature of 40 C and
a ﬂow rate of 0.2 ml min1: linear increase from 10% B to 95% B
within 35 min followed by holding 95% B for additional 2 min.
The retention time of native BI-32169 was 22.2 min, of the reduced
form 21.8 min and of the reoxidized BI-32169 22.2 min,
respectively.
CID fragmentation studies within the linear ion trap were done
using either online LC–MS or puriﬁed BI-32169 samples, which
were analyzed using a syringe pump at a ﬂow rate of 10 ll min1.
Usually, the doubly charged ions were selected for fragmentation
in the ion trap applying normalized collision energy of 35.
2.3. NMR spectroscopy and structure calculations
Five milligrams of native BI-32169 were dissolved in 250 ll
DMSO-d6, ﬁlled into Wilmad 3 mm tubes (Rototec Spintec) and
spectra were recorded at 313 K on a Bruker Avance 600 MHzspectrometer equipped with an inverse probe with z-gradient.
For sequential assignment [16], DQF-COSY, TOCSY, NOESY, and
ROESY were performed in phase-sensitive mode using States-TPPI
[17]. TOCSY spectra were recorded with mixing times of 50 and
80 ms. NOESY spectra were taken at 70, 100, 150, and 300 ms mix-
ing times, while ROESY spectra at 200 ms were observed. 1D spec-
tra were acquired with 65536 data points, while 2D spectra were
collected using 4096 points in the F2 dimension and 512 incre-
ments in the F1 dimension. For 2D spectra 32 transients were used.
Relaxation delay was 2.5 s. Chemical shifts were referenced to the
solvent signals. All spectra were processed with Bruker TOPSPIN
2.1. NOESY spectra with mixing times of 70 and 100 ms were ana-
lyzed using Sparky [18] and distance constraints were derived
using CYANA 2.1 [19]. Structure calculation was performed with
those obtained at 100 ms. For details of torsion angle constraints
see Supplementary data. The resulting constraints were used in
the simulated annealing protocol and structure calculations were
performed with CYANA 2.1. The calculated structures were engi-
neered by Sybyl 7.3 [20] to include the intramolecular isopeptide
linkage, followed by energy minimization under NMR constraints
using TRIPOS force ﬁeld within Sybyl. The quality of the ﬁfteen
lowest energy structures was evaluated using PROCHECK-NMR
[21] and the coordinates of these structures representing the solu-
tion structure of BI-32169 have been deposited in the Biological
Resonance Data Bank (BMRB) (accession number 20105).
3. Results
3.1. Mass spectrometric analysis of BI-32169
BI-32169 was successfully puriﬁed upon fermentation of Strep-
tomyces sp. (DSM 14996) by methanol extraction of the mycelium
followed by preparative HPLC (Supplementary Fig. 1). The puriﬁed
peptide could be reduced by DTT addition in a 6 M GdmCl contain-
ing sodium phosphate buffer at pH 8 (Supplementary Figs. 2 and
3). To determine, whether BI-32169 is a branched cyclic peptide
forming an additional cycle upon disulﬁde bond formation be-
tween Cys6 and Cys19, or is a lasso-structured peptide, mass frag-
mentation studies (MS2) of the native and reduced states were
performed. In general, lasso peptides show a weak overall frag-
mentation behavior due to their rigid structure, whereas in
branched cyclic peptides the exocyclic linear part usually produces
fragment ions in good yields [22]. In consideration of these
different MS2 fragmentation behaviors, gas phase fragmentation
studies of the m/z 1019.5 doubly protonated species of native
BI-32169 were conducted and a weak overall fragmentation
behavior was observed (Fig. 2). The most intense ions resulted
from the loss of either Ile10 or Ile10 and H2O (m/z 962.7 and
953.9), and from the loss of neutral molecules (e.g. CO and H2O).
The remaining fragment ions arose from at least three different
series of double peptide bond breakages. The dominating series
Fig. 2. MS2 spectrum of them/z 1019.5 doubly protonated species of native BI-32169. The peaks shown in red represent the fragment ions shown schematically, while peaks
shown in blue represent ions generated upon loss of water. All fragments observed result from two peptide bond cleavages, indicated by the red and black bars, yielding a
linear and a branched cyclic fragment. Doubly charged fragment ions are marked with an asterisk.
Fig. 3. MS2 spectrum of the m/z 1020.5 doubly protonated species of reduced BI-
32169. The peaks shown in red represent the fragment ions shown schematically,
while peaks shown in blue represent ions generated upon loss of water. Doubly
charged fragment ions are marked with an asterisk.
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nally located breakages resulting in both linear peptide fragments
of 3–8 amino acids in size (e.g. [P11GW13]+ and [P11GWNTPWA18]+)
and the remaining branched cyclic peptide fragments, which still
contained the disulﬁde linkage. Furthermore, two series of very
low intensity ions were found including peptide bond breakages
N-terminal of Ile10 and C-terminal of Trp17 in combination with
an additional breakage C-terminally or N-terminally, respectively.
In conclusion, to detect fragment ions of native BI-32169, two pep-
tide bond breakages have to occur and the observed fragmentation
pattern showed that the peptide bonds between I10-P11, D9-I10 and
W17-A18 are more susceptible to breaking. However, based on the
MS2 studies of the native state, we could not distinguish between
a bicyclic and a lasso-structured peptide, as the weak fragmenta-
tion behavior could also be a consequence of the fact that two bond
breakages are required rather than the supposed lasso structure.
Therefore, we conducted gas phase fragmentation studies of the
m/z 1020.5 doubly protonated species of the reduced BI-32169. A
weak overall fragmentation behavior was observed again (Fig. 3),
but the MS2 spectrum differed signiﬁcantly from the spectrum of
native BI-32169 (Fig. 2). All observed fragments originated from
single peptide bond breakages within the linear C-terminal tail ex-
cept the ion of m/z 839.6, which represents the internal fragment
ion [PGWNTPW]+. B and/or y ions corresponding to the single
cleavage of every peptide bond within the linear C-terminus were
detected apart from the ions generated upon cleavage C-terminal
to either Pro11 or Pro16. The most abundant fragment ion of m/z
959.9 resulted from the loss of the C-terminal Cys19. In summary,
the intensities of the fragment ions resulting from peptide bond
cleavages in the C-terminal tail of reduced BI-32169 were weaker
than one would expect for a branched cyclic peptide.
In addition the reduced form, which displayed a retention time
of 21.8 min, was reoxidized by exposure to air yielding native BI-
32169, as the reoxidized peptide showed the same retention time
(22.2 min) in HPLC–MS analysis (Supplementary Fig. 4) and an
identical MS2 spectrum compared to the natural product. Further-
more, heating experiments of reduced BI-32169 in 6 M GdmCl at
95 C did neither lead to changes in the retention time nor in the
fragmentation behavior.3.2. NMR spectroscopic studies on BI-32169
To ﬁnally prove our assumption, the structure of BI-32169 was
further characterized by NMR spectroscopy. 1H spectra were re-
corded at various temperatures yielding the best resolution at
313 K (Supplementary Fig. 5), which was used for all further 2D
experiments. DQF-COSY, TOCSY and NOESY spectra were used to
fully assign all 1H signals (Supplementary Figs. 6–8 and Table 1).
Fig. 4. Solution structure of BI-32169. Backbone superimposition of 15 lowest
energy structures of BI-32169 shown in stereoview. The isopeptide bond (red)
between Gly1 and Asp9 results in a macrolactam ring (yellow) through which the
C-terminal tail (blue) is threaded. The C-terminus is covalently linked to the ring by
a disulﬁde bridge (green) between Cys6 and Cys19.
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indicating all four proline residues to be in the trans conformation.
Strong NOEs between NH of Gly1 and the side chain protons of
Asp9 were observed providing direct evidence of the internal iso-
peptide linkage. Additional long-range NOEs were detected be-
tween Gly1 and Trp13, Leu2 and Trp13, Leu2 and Asn14, Pro3
and Trp13, Gly5 and Thr15, Gly5 and Pro16, Cys6 and Thr15,
Pro7 and Asn14, Ser8 and Thr15, Asp9 and Asn14, and Asp9 and
Thr15. These long-range NOE contacts indicated a threading of
the C-terminal tail through the 9-residue ring. Furthermore, NOE
contacts between Cys6 and Cys19 were observed conﬁrming the
formation of the disulﬁde bridge (Supplementary Fig. 9).
Structure calculations were carried out on the basis of 154
distance constraints, including 36 backbone, 50 long-range and
68 side chain constraints. The isopeptide linkage was considered
by setting a distance constraint between N of Gly1 and Cc of
Asp9 to 1.33 Å yielding on average 8.1 distance constraints per
residue. Details of applied torsion angle constraints are described
in Supplementary data.
The calculation was initiated with 50 random conformers. In
consideration of low energies and minimal violations of the exper-
imental data, a family of 15 structures was chosen which show an
average root-mean-square deviation (rmsd) for the backbone of
0.04 Å (Table 1) and no residues in disallowed regions of the Rama-
chandran plot (Supplementary Fig. 10). These 15 energy-mini-
mized conformers represent the solution structure of BI-32169
and deﬁnitely prove the assumed lasso structure (Fig. 4). The 10-
residue tail is threaded through the 9-residue N-terminal macro-
lactam ring, placing Ile10-Asn14 above and Thr15-Cys19 below
the plane of the macrocycle. The disulﬁde bond between the C-ter-
minal Cys19 and Cys6 ﬁxes the threading C-terminal tail on the
opposite side of the ring and generates an inﬂexible peptide scaf-
fold resembling a clef. The two proline residues Pro11 and Pro16
introduce two kinks within the tail resulting in a twisted S-like
structure, in which the ﬁrst kink involving Ile10-Trp13 can be clas-
siﬁed as a type I b-turn. This twisted S-like structure facilitates the
threading of the tail through the ring and sets the two Cys residues
in close proximity enabling disulﬁde bond formation. The shape of
BI-32169, as represented by the accessible surface (Fig. 5A), can be
described as globular. Most of the amide protons are buried within
the compact lasso structure, in agreement with very low tempera-
ture coefﬁcients of the 1H chemical shifts observed (Supplemen-
tary Fig. 5). Thr15 showed a temperature coefﬁcient of almost
null, which was previously observed for Ser14 of capistruin, consis-
tent with the localization of the peptide bond between Asn14 and
Thr15 within the macrocyclic ring. The main interactions stabiliz-
ing the compact lasso fold are van der Waals interactions of the al-
most completely hydrophobic amino acid side chains, also
reﬂected by the poor solubility in polar solvents (e.g. water or
methanol). In conclusion, tandem mass spectrometric and NMR
spectroscopic studies prove that the glucagon receptor antagonist
BI-32169 is a lasso-structured peptide, as assumed from its pri-
mary structure.Table 1
Structural statistics for the family of 15 structures representing the solution structure
of BI-32169.
Restraining constraints Constraints violations
Total: 154 Distance violations, >0.5 Å: 0
Distance, i = j: 47 RMS deviations: 0.025 Å
Distance, |i  j| = 1: 57 Dihedral violations, >5: 0
Distance, |i  j| > 1: 50 RMS deviation: 2.4
Dihedral: 24 Average pairwise RMS deviation (Leu2-Ala18)
Hydrogen bond: 0 Backbone atoms: 0.04 Å
Constraints/residue: 9.4 All heavy atoms: 0.07 Å4. Discussion
By MS- and NMR-based structure elucidation the glucagon
receptor antagonist BI-32169 was proven to adopt the lasso fold,
which was predicted based on similarities of its primary structure
to known lasso peptides. As BI-32169 shares characteristic features
with representatives of both lasso peptide classes [7], we suggest
that BI-32169 establishes a new class of lasso peptides, termed
class III, which is characterized by a Gly at position 1 and two cys-
teine residues forming one disulﬁde bridge between the macrolac-
tam ring and the C-terminal tail.
The dominating ion series in the MS2 spectrum of native BI-
32169 (Fig. 2) involved the breakage N-terminal to Pro11. Gener-
ally, peptide bond cleavages N-terminal to proline are frequently
observed yielding fragment ions of high intensity [23]. Therefore
it is noticeable, that in case of native BI-32169 fragments following
a cleavage N-terminal to Pro16 are less abundant, which is most
likely caused by a lower accessibility of the peptide bond, as it is
located directly below the macrolactam ring. This tendency was
also observed in the MS2 spectrum of reduced BI-32169 (Fig. 3).
Additionally, the reduced form displays a weak overall fragmenta-
tion behavior previously reported for class II lasso peptides
[1,2,22], is converted into the native structure upon reoxidation
(Supplementary Fig. 4) and no additional chromatographic signal
is observed upon heating, as recently described for the heat-labile
capistruin R15A/F16A variant [13]. Therefore it can be concluded
that the reduced BI-32169 still represents a stable lasso peptide.
In native BI-32169 the disulﬁde bond between Cys6 located within
the macrolactam ring and the C-terminal Cys19 links the threading
tail to the ring preventing an unthreading of the lasso fold by a
covalent bond. In the reduced form this covalent linkage is not
present. However, the sterically demanding side chain of Trp17 is
located below the macrocycle and most likely fulﬁlls the function
of the disulﬁde bridge non-covalently by trapping the threading
tail by steric hindrance (Fig. 5B and C), a widespread strategy in
class II lasso peptides [1–3,22,24]. This may have an important im-
pact on BI-32169 biosynthesis because if the disulﬁde bond is
formed after generation of the lasso fold either enzymatically or
by spontaneous oxidation, the trapping of the tail by Trp17 would
be necessary to prevent an unfolding of the lasso structure. In this
case Trp17 would represent a safety lock prior to disulﬁde bond
formation.
The determined lasso structure of the glucagon receptor antag-
onist BI-32169, which apparently displays a sought-after biological
activity, opens new avenues of derivatization. In the US patent
regarding the use of BI-32169 and derivatives thereof for glucagon
receptor inhibition the solid phase peptide synthesis (SPPS) of
these bicyclic compounds was claimed [25]. Taking into account
Fig. 5. Structural features of BI-32169. (A) Overall shape of BI-32169. Accessible surface is shown in transparent grey. (B) Interactions between the ring (orange) and the C-
terminal tail (colored by element). The surface of the ring and of the Trp13 and Trp17 side chains are shown. (C) Derived from (B) by 60 rotation along the x-axis.
T.A. Knappe et al. / FEBS Letters 584 (2010) 785–789 789the lasso structure of BI-32169, which is certainly needed for bio-
logical activity, and the fact that no lasso peptide has been synthe-
sized so far by SPPS due to the folding challenge, standard SPPS will
not yield BI-32169 or its derivatives. However, this obstacle can be
overcome by an in vivo biosynthetic approach. All currently known
gene clusters of lasso peptides reveal a ribosomal origin [1,26] and
mutagenesis studies of MccJ25 [12] and capistruin [13] showed a
high promiscuity of the biosynthetic machinery allowing in vivo
production of variants upon mutagenesis of the precursor protein.
This approach should facilitate an optimization of the already
present glucagon receptor antagonistic activity or the introduction
of new biologically active peptide sequences within the rigid
BI-32169 scaffold.
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